Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028

Boundless Bio, Inc.

2025-Q3 EPS reported -$2.03

Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).
Cash, cash equivalents and short-term investments of $117.6M as of Sept 30, 2025.
Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial.
IND submission for BBI-940 on track; Phase 1 trial expected in H1 2026.
Cash runway into first half of 2028 through proof-of-concept clinical readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.